ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1497

Clinical and Laboratory Features of Patients with Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy for Sicca Symptoms: A 16 Year Experience

Bibi Ayesha1, Ruth Fernandez-Ruiz2, Devin Shrock3, Rebecca Tuetken4, Scott Lieberman5, Elizabeth Field6 and Namrata Singh7, 1Internal Medicine and Division of Rheumatology, MD, BRONX, NY, 2Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 3Pathology, MD, Iowa, IA, 4MD, PhD, Iowa, IA, 5Division of Rheumatology, Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 6Iowa City VA, Iowa City, IA, 7VA Nebraska-Western Iowa Health Care System and University of Iowa, Omaha, IA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: biopsies, Salivary gland, serologic tests and sialoadenitis, SICCA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Sjögren's Syndrome Poster II: Clinical Research

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Focal lymphocytic sialadenitis (FLS) on minor salivary gland biopsy (MSGB) is one of the classification criteria for Sjögren’s syndrome (SS). As no diagnostic criteria exist, there is a need for timely diagnosis of seronegative patients (SSA and SSB antibody negative), to allow earlier intervention and prevent end-organ damage. There are only a few studies on how seronegative patients with FLS on MSGB differ clinically from seropositive patients (SSA and/or SSB antibody positive). Therefore, the objective of our study was to compare the clinical and laboratory features of patients with and without autoantibodies (anti-SSA and/or anti-SSB) among those with FLS on MSGB. As a secondary objective, we compared the clinical and laboratory features of those with and without FLS on MSGB among the seronegative patients only.

Methods: Cases > 18 years old with a MSGB performed at the University of Iowa Hospital and Clinics between 1/1/2000-12/31/2016 were identified, excluded patients with incomplete clinical and laboratory data. Then data was extracted by retrospective chart review. Fisher’s exact test or chi-square test was used to compare categorical variables between the groups; student’s t-test was used for comparison of continuous variables.

Results: During the study period 230 patients had MSGB done for sicca symptoms, 51 patients were excluded due to incomplete clinical data. FLS on MSGB was found in 133 patients, 27% (37/133) were seropositive and 72% (96/133) were seronegative. Dry eyes, dry mouth, fibromyalgia and depression, predominated as statistically significant clinical features in the seronegative group compared to the seropositive group (Table1– Among all MSGB positive patients, comparison of the clinical and laboratory features of those with and without SSA antibody and/or SSB antibody). Symptomatic seronegative patients who underwent MSGB were 137, and no FLS on MSGB was found in 41 patients. Smoking predominated as a statistically significant variable (p=0.0003) in the seronegative patients with no FLS on biopsy, whereas seronegative patients with a positive biopsy tended to be older and have more sicca symptoms.

Conclusion: Identifying the subset of symptomatic SS patients, who are seronegative is challenging. When patients have sicca symptoms, associated with other clinical features like fatigue, inflammatory arthritis, peripheral nervous system clinical symptoms; with no serological markers, these patients should be considered for a further evaluation by MSGB. Smoking can also cause sicca symptoms with no FLS on MSGB, this should be considered while evaluating the patients with sicca symptoms.

TABLE 1


Disclosure: B. Ayesha, None; R. Fernandez-Ruiz, None; D. Shrock, None; R. Tuetken, None; S. Lieberman, None; E. Field, None; N. Singh, None.

To cite this abstract in AMA style:

Ayesha B, Fernandez-Ruiz R, Shrock D, Tuetken R, Lieberman S, Field E, Singh N. Clinical and Laboratory Features of Patients with Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy for Sicca Symptoms: A 16 Year Experience [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-and-laboratory-features-of-patients-with-focal-lymphocytic-sialadenitis-on-minor-salivary-gland-biopsy-for-sicca-symptoms-a-16-year-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-laboratory-features-of-patients-with-focal-lymphocytic-sialadenitis-on-minor-salivary-gland-biopsy-for-sicca-symptoms-a-16-year-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology